Evidence map›Paper›PMID 30687321›Full record

ReviewFrontiers in immunology2018

Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis.

Hans Lassmann

4 registry-linked trialsOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 389 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
389citing papers in PubMed, 11 pooled it
45.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04944251 nacompletednot on this mapstarted 2019, after this paper: background citation

Exercise in Persons With Multiple Sclerosis

TypeinterventionalSponsorEge UniversityRan2019 to 2020Enrolled43ConditionsMultiple Sclerosis, Exercise Intervention, Neuro-Degenerative DiseaseArmsRegular Exercise
NCT05245344 unknown statusnot on this mapstarted 2022, after this paper: background citation

Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study

TypeobservationalSponsorNeuromed IRCCSRan2022 to 2023Enrolled154ConditionsRelapsing-Remitting Multiple Sclerosis (RRMS), Neuromyelitis Optica, HealthyArmsPeripheral blood withdrawal
NCT05961644 phase2 / phase3recruitingnot on this mapstarted 2022, after this paper: background citation

Safety and Efficacy of Subcutaneous Cladribine for Nonrelapsing, Secondary Progressive Multiple Sclerosis (CLASP-MS): a Randomized, Placebo-controlled, Double-blind, Phase 2 Study.

TypeinterventionalSponsorInstitute of Psychiatry and Neurology, WarsawRan2022 to 2027Enrolled188ConditionsMultiple Sclerosis, Secondary Progressive, Multiple SclerosisArmsCladribine Subcutaneous Injection, 0.9% Chloride Injection Sodium
NCT06841068 phase1 / phase2withdrawnnot on this mapstarted 2026, after this paper: background citation

A Phase I/II Trial of Intrathecal Delivery of Amniotic Fluid Stem Cells for Primary and Secondary Progressive Multiple Sclerosis

TypeinterventionalSponsorWake Forest University Health SciencesRan2026 to 2026Enrolled0ConditionsMultiple Sclerosis, ProgressiveArmsAmniotic fluid or placental CD117 stem cells
3 · Its place in the literature

Who cites it

389 citing papers in PubMed, 11 syntheses or guidelines pooled it, 633 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Changes in Gut Microbiota and Multiple Sclerosis: A Systematic Review.International journal of environmental research and public health · 2023
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. MWF of the corpus callosum is a robust measure of remyelination: Results from the ReBUILD trial.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Trial
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

329 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Hans LassmannCenter for Brain Research, Medical University of Vienna, Vienna, Austria.
Medical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the majority of patients multiple sclerosis starts with a relapsing remitting course (RRMS), which may at later times transform into secondary progressive disease (SPMS). In a minority of patients the relapsing remitting disease is skipped and the patients show progression from the onset (primary progressive MS, PPMS). Evidence obtained so far indicate major differences between RRMS and progressive MS, but no essential differences between SPMS and PPMS, with the exception of a lower incidence in the global load of focal white matter lesions and in particular in the presence of classical active plaques in PPMS. We suggest that in MS patients two types of inflammation occur, which develop in parallel but partially independent from each other. The first is the focal bulk invasion of T- and B-lymphocytes with profound blood brain barrier leakage, which predominately affects the white matter, and which gives rise to classical active demyelinated plaques. The other type of inflammation is a slow accumulation of T-cells and B-cells in the absence of major blood brain barrier damage in the connective tissue spaces of the brain, such as the meninges and the large perivascular Virchow Robin spaces, where they may form aggregates or in most severe cases structures in part resembling tertiary lymph follicles. This type of inflammation is associated with the formation of subpial demyelinated lesions in the cerebral and cerebellar cortex, with slow expansion of pre-existing lesions in the white matter and with diffuse neurodegeneration in the normal appearing white or gray matter. The first type of inflammation dominates in acute and relapsing MS. The second type of inflammation is already present in early stages of MS, but gradually increases with disease duration and patient age. It is suggested that CD8

Indexed as

Blood-Brain BarrierB-LymphocytesDisease ProgressionGlymphatic SystemHumansMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Relapsing-RemittingSpinal CordT-LymphocytesWhite Matterdemyelinationinflammationneurodegenerationprimary progressive MSrelapsing remitting MSsecondary progressive MS

Identifiers

PMID30687321
PMCPMC6335289
OpenAlexW2909270098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.